# Pizarra — PT-pseudo_0bd72f429a8b (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_0bd72f429a8b
Task: 1

Encounter: Urology - outpatient on 11 Jan 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 56-year-old male
  - PSA: 5.3 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.1 ng/mL²
  - PSA velocity: 2.26 ng/mL/yr
  - Prior PSA: 2.7 ng/mL
  - Prostate volume: 48.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.40281674 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Obesity (BMI >30)
  - Problem list / PMHx: Obesity (BMI >30)
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 5.3 ng/mL. PI-RADS 4. PSAD 0.10. Prostate volume 48 mL. DRE nodus. csPCa 0.40.

Vitals: weight 79 kg, height 175 cm, BMI 25.8, BP 123/64 mmHg, HR 80 bpm. Smoking: Ex-smoker (33 pack-yr, quit 2021).

Chief complaint: Request for clinical re-evaluation driven by previous biopsy results and a current PSA elevation to 5.3 ng/mL.

History: A 56-year-old retired bank clerk first entered investigation during early 2023 after a PSA elevation triggered a positive biopsy and subsequent monitoring protocol. He is married and shares his residence with his partner, maintaining a fairly active routine that includes cycling roughly 20 kilometres twice weekly. Lower urinary tract symptoms register at a moderate IPSS of 11, with no reports of pelvic pain or haematuria. After accumulating 33 pack-years of smoking, he ceased tobacco use in 2021. Alcohol intake stays near one unit per week. Unrelated urological issues include uncomplicated cataract surgery performed three years prior and routine podiatry visits. He previously opted out of research trials and currently maintains a BMI exceeding 30 without any active medications.

Physical examination: DRE — texture: moderately enlarged gland with a distinct Nodus palpable in the left peripheral zone; mobility: unrestricted. General assessment shows stable vital signs, absent lymphadenopathy, and no bone tenderness.

Patient info: retired bank clerk; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 1 units / week; exercise Cycling 2x/week, ~20 km; IPSS score: 11/35 (moderate LUTS).

Recent other appointments: Podiatry — routine foot care.
Admin: Patient declined research participation previously; respect for AS-related trials.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.27 +/- 0.18   (95% CI 0.02-0.69)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.10  (few labelled cases resemble this one)
  - 5.2 effective neighbours out of 10; 0 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'supports': A +/- dA does not cross 0.5, but A +/- 1.96*dA does. There is a direction, not a conclusion. Measured accuracy in this tier: 0.67. Treat it as a weighted vote, not as a decision.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=5.3, age=56.0, psad=0.1, dre_ord=1.0, vol=48.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the patient's PSA velocity (2.26 ng/mL/yr), the prior PSA (2.7 ng/mL), or the specific findings from the mpMRI report (PI-RADS 4) in conjunction with the PSA density (0.1 ng/mL²).

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests NO BIOPSY with a wide interval (95% CI 0.02-0.69). This wide interval suggests high aleatoric uncertainty. A failure mode is that the prior does not account for the rising PSA velocity (2.26 ng/mL/yr) or the fact that the patient has a prior positive biopsy, which fundamentally changes the question from "does he have cancer" to "is the cancer progressing/recurrent." Another failure mode is ignoring the PI-RADS 4 score in the context of the rising PSA.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <laboratory results> -> <full panel> -> If the lab panel shows significant changes in other markers (e.g., specific tumor markers, if available), it could refine the risk assessment.
  <PSA history> -> <trend / velocity beyond the headline value> -> If the trend is significantly steeper or more concerning than the 2.26 ng/mL/yr, it would increase the suspicion for biopsy.
  <radiology / mpMRI report> -> <full mpMRI prose behind the headline imaging values> -> The detailed prose might offer context for the PI-RADS 4 score that the structured panel misses.
  <previous GP / urology consultation notes> -> <previous notes> -> These notes might detail the rationale for the prior biopsy and the monitoring protocol, which is crucial for interpreting the current situation.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **mpMRI Report (10 Jan 2025):**
  "PI-RADS 4 lesion in the left peripheral zone, base/mid. Prostate volume 48.0 mL; PSAD 0.1 ng/mL/mL. csPCa predicted probability 0.40281674."

  **PSA History Trend:**
  `[{"date": "Jan 2023", "val": 3.5}, {"date": "Jan 2024", "val": 3.5}, {"date": "Jan 2025", "val": 5.3}]` (Indicates a rise from 3.5 to 5.3 over two years).

  **Previous Notes:**
  `[{"date": "22 Jan 2023", "author": "Dr. F. de Boer (GP)", "text": "Initial referral occurred after a routine health screen recorded a PSA reading of 1.5 ng/mL. The concurrent digital rectal examination yielded normal findings, after which multiparametric MRI and targeted biopsy were ordered. Subsequent histopathology confirmed low-risk prostate cancer, and the patient entered an active surveillance protocol featuring quarterly PSA checks and annual MRI evaluations."}, {"date": "13 Sep 2024", "author": "Dr. F. de Boer (GP)", "text": "A January 2024 follow-up test showed the PSA level increasing to 2.7 ng/mL, which triggered plans for a repeat MRI that were ultimately postponed due to scheduling limits. With the latest measurement now at 5.3 ng/mL and a calculated velocity of 2.26 ng/mL/yr, administrative routing was initiated to return the case to urology for re-evaluation. Urinary function remains unaffected, and his weekly cycling routine continues unchanged."}]`

  **Laboratory Results (27 Nov 2024):**
  `[{"name": "PSA", "val": "5.3 ng/mL", "date": "27 Nov 2024", "flag": "H"}, {"name": "Free PSA", "val": "1.37 ng/mL", "date": "27 Nov 2024", "flag": ""}, {"name": "%Free PSA", "val": "26%", "date": "27 Nov 2024", "flag": ""}, {"name": "Haemoglobin", "val": "15.0 g/dL", "date": "27 Nov 2024", "flag": ""}, {"name": "WBC", "val": "6.1 x10^9/L", "date": "27 Nov 2024", "flag": ""}, {"name": "Platelets", "val": "180 x10^9/L", "date": "27 Nov 2024", "flag": ""}, {"name": "Creatinine", "val": "91 umol/L", "date": "27 Nov 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "27 Nov 2024", "flag": ""}, {"name": "Testosterone", "val": "15.0 nmol/L", "date": "27 Nov 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "79 U/L", "date": "27 Nov 2024", "flag": ""}, {"name": "LDH", "val": "271 U/L", "date": "27 Nov 2024", "flag": ""}]`

NOT RETRIEVED
  get_family_history: Not called because the retrieval economy suggests it is not necessary for this specific decision point, as per the tool description.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PSA velocity of 2.26 ng/mL/yr.
  PSA has risen from 3.5 ng/mL in Jan 2023 to 5.3 ng/mL in Jan 2025.
  mpMRI shows a PI-RADS 4 lesion in the left peripheral zone.
  Patient is currently outside the initial surveillance protocol due to PSA elevation.

  AGAINST sampling this patient now:
  Prior biopsy was positive (though the report is not retrieved, the status is noted).
  csPCa predicted probability is 0.40281674.

WHERE THIS LEANS
  The retrieved evidence strongly suggests a concerning trajectory (rising PSA velocity and PI-RADS 4 finding) that contradicts the statistical prior of NO BIOPSY. This leans towards considering a biopsy to re-evaluate the known pathology and the progression of the disease.

[Sections actually revealed in this consultation: psa_trend, radiology_report, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

A biopsy is recommended because the patient has a history of a positive biopsy, shifting the question to whether the known cancer is progressing. This is supported by the rising PSA velocity of 2.26 ng/mL/yr and the presence of a PI-RADS 4 lesion. The evidence strongly suggests a concerning trajectory that warrants re-evaluation of the known pathology.

Variables that carried weight: bx=decisive, age=noted, psa=decisive, vol=noted, psad=noted, pirads=important
Sections revealed: psa_trend, radiology_report, previous_notes, laboratory_results
